Apnimed (APMD) Prices $192M IPO at Top of Range for First Oral Sleep Apnea Pill

Apnimed (APMD) priced its IPO on Thursday night, July 30, 2026, upsizing the offering 20% from 10 million to 12 million shares and pricing at $16.00 — the top of its $14-$16 range — to raise $192 million. The IPO was multiple times oversubscribed. Shares begin trading Friday, July 31, on the Nasdaq under the ticker APMD. The offering values the Cambridge, Massachusetts-based company at approximately $608 million.

The raise is the largest biotech IPO of 2026, surpassing Scribe Therapeutics’ $128.7 million offering priced at the top of its range on July 23. BofA Securities, Evercore ISI, Cantor, and LifeSci Capital served as joint book-runners.

The drug: first oral pill for sleep apnea

Apnimed’s only clinical candidate is AD109, branded Oxnimbi — a once-daily oral fixed-dose combination of aroxybutynin (a novel antimuscarinic) and atomoxetine (a norepinephrine reuptake inhibitor already used in ADHD). The drug targets the neuromuscular root cause of obstructive sleep apnea (OSA) by boosting upper airway muscle activity during sleep to prevent airway collapse, rather than relying on sedation or weight loss.

The NDA was accepted by the FDA in July 2026 with a PDUFA target action date of February 28, 2027, and Fast Track designation. If approved, Oxnimbi would be the first prescription pill designed specifically for OSA across all severity levels.

Eli Lilly’s Zepbound (tirzepatide) became the first FDA-approved drug for OSA in December 2024, but only for adults who also have obesity. AD109 is being developed for OSA patients regardless of weight, a broader population.

The Phase 3 data

AD109 met its primary endpoint in both registrational Phase 3 trials — SynAIRgy and LunAIRo — which together enrolled over 1,300 patients, the largest clinical program of an investigational OSA medication to date.

In the LunAIRo trial (660 patients), AD109 achieved a mean reduction in the Apnea-Hypopnea Index (AHI) of 46.8% from baseline at 26 weeks versus 6.8% with placebo (p<0.001). In SynAIRgy, the mITT population saw a 55.6% mean AHI reduction at 26 weeks versus 19.1% with placebo (p<0.0001). Both trials also showed statistically significant improvements in secondary oxygenation endpoints, including the oxygen desaturation index (ODI3) and hypoxic burden (HB4).

The reduction in AHI remained significant at 51 weeks in LunAIRo, suggesting durable efficacy. No serious adverse events related to AD109 were reported.

The market: 80 million US patients, no oral drug

OSA affects an estimated 80 million Americans and roughly one billion people worldwide. The standard of care is CPAP (continuous positive airway pressure), which requires wearing a mask all night and has adherence rates below 50%. No other oral pharmacotherapy is in Phase 3 development for OSA, leaving AD109 with no direct competitive pipeline threat.

Shionogi, the Japanese pharmaceutical company that discovered Crestor (rosuvastatin), is a principal stockholder, adding pharma credibility. Apnimed reported a net loss of $31.83 million on revenue of $120.15 million for the 12 months ended March 31, 2026, per the prospectus.

What to watch

The IPO proceeds fund the regulatory approval process and commercial launch. The binary catalyst is the February 28, 2027 PDUFA — either the FDA approves the first oral OSA drug and creates a new market category, or issues a Complete Response Letter. Key questions are whether the AHI reduction and oxygenation improvements are clinically meaningful enough for FDA approval, and whether payers will cover an oral drug for a condition long managed by devices. First-day trading performance on July 31 will signal institutional appetite for the largest sleep medicine IPO in years.

For more on the broader obesity and metabolic drug market, see our coverage of GLP-1 stocks and the $100 billion obesity opportunity.